Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 employees in 79 countries, and markets its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Important safety information regarding NovoPen® Echo® and NovoPen® 5
Novo Nordisk A/S has detected that the insulin cartridge holder used in a small number of NovoPen® Echo® and NovoPen® 5 batches may crack or break if exposed to certain chemicals, for example certain cleaning agents. NovoPen® Echo® and NovoPen® 5 are used for insulin treatment by people with diabetes.
Replacement of cartridge holder
Novo Nordisk urges people with diabetes using a NovoPen® Echo® and/or NovoPen® 5 from one of the affected batches to replace the cartridge holder as some could be damaged. Please check your device batch number against the list of affected batches which can be found here:
Please click here:
Novo Nordisk Hong Kong Limited
Tel: +852 2387 8555
DKSH Hong Kong Limited
Tel: +852 2895 9668
Your information about complaints and side effects helps us ensure the safe use of our products. If you have experienced a complaint or a side effect to a Novo Nordisk product, we encourage you to also report this to Novo Nordisk.
Please e-mail: email@example.com
or call us on +852 2387 8555
If you or the person you are reporting on behalf of are currently suffering from severe side effects, you should contact your local doctor or other medical health professional before reporting the side effect.
All personal information reported in relation to a complaint or a side effect will be processed in accordance with applicable data protection legislation:
• Your report is used solely for the scientific evaluation of the medicine and product quality
• Side effects are filed in our global safety database and the data is regularly analysed for overall patterns
• Novo Nordisk may share reported complaints and side effects with health authorities as mandated by law. However, no personally identifiable details will be shared
• Novo Nordisk will retain the data as long as required by law